Novo Nordisk launched a higher-dose version of Wegovy in the U.S., adding a 7.2 mg injection to its chronic weight management regimen. The product expansion focuses on patients requiring step-up dosing within the semaglutide obesity treatment framework. The move arrives as GLP-1 competition intensifies on both efficacy and dosing convenience across obesity portfolios. For manufacturers and clinicians, the immediate operational questions are dosing accessibility, patient retention through dose escalation, and how payers will handle coverage for the higher strength. The high-dose introduction will also be watched for downstream effects on market share dynamics, given ongoing rivalry with oral and injectable GLP-1 programs.